Trial · NCT02048813
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) Rate at 3 Years | Assessed every 3 months until progression up to 4 years and 8 months | All randomized patients were included in this analysis. | Proportion of participants | NUMBER |
| SECONDARY | Overall Survival (OS) Rate at 3 Years | Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5, up to 4 years and 8 months | All randomized patients were included in this analysis. | Proportion of participants | NUMBER |
| SECONDARY | The Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Trial Outcome Index (TOI) Score at 6 Months | Assessed at 6 months | |||
| SECONDARY | The Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Trial Outcome Index (TOI) Score at 12 Months | Assessed at 12 months | |||
| SECONDARY | The Association Between Baseline Rai Stage and Complete Response (CR) Rate | Assessed at baseline, every 3 months for the first 2 years, and every 6 months for years 3-5 | |||
| SECONDARY | Progression-free Survival (PFS) by Measurable Residual Disease (MDR) Status at 2 Years | Assessed every 3 months until progression up to 5 years | |||
| OTHER_PRE_SPECIFIED | Distribution of Genetic Abnormalities Before and After Treatment | Assessed at baseline, and 3, 6, 12, 15, 18, 24, 36 months | |||
| OTHER_PRE_SPECIFIED | T-cell Counts at 12 Months | Assessed at 12 months | |||
| OTHER_PRE_SPECIFIED | Association Between Single Nucleotide Polymorphisms (SNPs) and PFS | Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5 | |||
| OTHER_PRE_SPECIFIED | Prognostic Model to Predict PFS | Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5 | |||
| OTHER_PRE_SPECIFIED | Signaling Networks Downstream of the B-cell Receptor | Assessed at baseline and 3, 6, 12, 15, 18, 24, 36 months | |||
| OTHER_PRE_SPECIFIED | Collection of Relapse Samples | Assessed at relapse |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02048813/outcomes